Compare OBK & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OBK | MPLT |
|---|---|---|
| Founded | 1912 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | 2018 | 2025 |
| Metric | OBK | MPLT |
|---|---|---|
| Price | $51.90 | $8.62 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 15 |
| Target Price | ★ $59.20 | $26.54 |
| AVG Volume (30 Days) | 156.9K | ★ 418.3K |
| Earning Date | 10-28-2026 | 08-13-2026 |
| Dividend Yield | ★ 1.94% | N/A |
| EPS Growth | N/A | ★ 82.39 |
| EPS | ★ 1.97 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.68 | N/A |
| Revenue Next Year | $7.47 | N/A |
| P/E Ratio | $26.25 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $32.13 | $8.70 |
| 52 Week High | $55.57 | $40.43 |
| Indicator | OBK | MPLT |
|---|---|---|
| Relative Strength Index (RSI) | 40.47 | 25.82 |
| Support Level | $50.64 | N/A |
| Resistance Level | $53.05 | $14.22 |
| Average True Range (ATR) | 0.93 | 0.59 |
| MACD | -0.14 | 0.02 |
| Stochastic Oscillator | 30.14 | 6.73 |
Origin Bancorp Inc is a financial holding company that provides personalized, relationship banking to businesses, municipalities, and personal clients in the communities it serves. The company offers a broad range of financial services and operates more than 56 locations in Dallas/Fort Worth, East Texas, Houston, North Louisiana, Mississippi, South Alabama, and the Florida Panhandle. It also provides insurance agency products and services through its wholly owned insurance agency subsidiary. The company operates in one business segment, community banking, and is mainly engaged in attracting deposits from individuals and businesses and using these deposits and borrowed funds to originate commercial, residential mortgage, construction, and consumer loans.
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.